Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
XTL Biopharmaceuticals Ltd. Sponsored ADR ( (XTLB) ) has provided an announcement.
XTL Biopharmaceuticals Ltd. announced its financial results for the nine months ending September 30, 2024, highlighting its acquisition of The Social Proxy, a web data company. Despite disruptions in Israel, the company has not experienced significant operational impacts, although financial challenges remain due to the regional conflict. The financial results show a decrease in cash and equivalents, with a reported operating loss of $1,360 thousand; however, the acquisition has contributed to increased revenues and affected various expense categories.
More about XTL Biopharmaceuticals Ltd. Sponsored ADR
XTL Biopharmaceuticals Ltd. is engaged in the biopharmaceutical industry, focusing on acquiring and developing therapeutics for the treatment of autoimmune diseases. The company holds an intellectual property portfolio for hCDR1, a treatment for Lupus disease (SLE), and has a subsidiary, The Social Proxy, a web data company.
YTD Price Performance: 104.95%
Average Trading Volume: 45,501
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $21.46M
Find detailed analytics on XTLB stock on TipRanks’ Stock Analysis page.
